Digene Taps Cytyc's 110 Physician Reps For Hybrid Capture 2 HPV Test
This article was originally published in The Gray Sheet
Executive Summary
Cytyc's 110-person direct sales force focusing on the physician market will offer Digene's Hybrid Capture 2 test for human papilloma virus in conjunction with Cytyc's ThinPrep automated Pap test under a Jan. 18 exclusive co-marketing agreement between the firms.
You may also be interested in...
Cytyc Gets Digene After Long Courtship, On Verge Of New Indication
The payback on Cytyc's $554 mil. acquisition of Digene could get a quick boost from Digene's pending primary screening indication for DNA Pap for cervical cancer
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.